7th Annual PREDiCT: Tumor Models Boston Summit

7th Annual PREDiCT: Tumor Models Boston Summit is organized by Hanson Wade and will be held from Jul 16 - 18, 2019 at Revere Hotel Boston Common, Boston, Massachusetts, United States of America.

Description:

The Tumor Models Conference Series is dedicated to exploring the latest advances in the application of preclinical models to enhance the translation of cancer therapies from bench to patient.

• Be at the interface of model innovation and therapeutic development,
• Meet a multidisciplinary mix of model developers, translational and pharmacology research scientists
• Share knowledge and debatewith the scientific community thanks to a human sized event
• Assess how the industry is overcoming challenges in drug development through the use of in vitro & in vivo models.
• The 3-day agenda, designed with the input of 40+ leading oncology leaders, will strive to answer your burning questions in terms of model validation, translatability and rationale
• Benchmark your progress and enhance the translational confidence of your preclinical approaches
• Join over 120 attendees from 80 organizations from various backgrounds such as academia, industry and model providing services and define the future of cancer drug development.

Workshop A

Tuesday, July 16
8:00 am - 11:00 am

Challenges, Insights & Future Directions for Experimental Models in Cancer Immunotherapy

Workshop Leader: Shiva Kazerounian, Associate Director, In Vivo Pharmacology Lead , Berg Pharma

Understanding tumor placement, immune composition, response to treatment, and molecular characterization for the model of interest can be invaluable when designing the most appropriate study for your research goals. However, major issues remain, not only in selecting and optimizing models and tools for cancer immunotherapy research, but in selecting who to work with and when. Discussions in this session will centre on:
• The range of current IO models available amongst their strengths and weaknesses
• Mouse syngeneic models, their genetic backgrounds and use in IO for mono or combination therapy
• How to identify, select and work with model developers and CRO’s available

Workshop B

Tuesday, July 16
11:30 am - 2:30 pm

Introduction & Overview to 3D High Content Screening Approaches

Workshop Leader: Alejandro Amador, Head, Scientific Leader Discovery Biology Automation, GSK

3D high content approaches offer significant opportunity for improving cancer drug discovery. However, there exists formidable technical hurdles for HCS methods and analytical approaches. The session will look to explore the current start-of the art alongside the emergence of new technologies and techniques enabling 3D HCS applications. Discussions will centre on the marriage of 3D and high-content screening (HCS) to discover targeted cancer drug therapies

Leave having explored:
• The value, impact and approaches for use of 3D-HCS within cancer discovery
• 3D High-content analysis algorithm approaches for HCS
• How multiparametric analyses can be incorporated to evaluate phenotypic compound effects

Workshop C

Tuesday, July 16
3:00 pm - 6:00 pm

Considerations in Modelling the Microenvironment

Workshop Leader: Esmaiel Jabbari, Professor , University of South Carolina

In the last few decades, cancer stem cells (CSC) have proven to play a key role in tumor initiation resistance and recurrence. Recent advances have also begun to elucidate the complex cross talk at different stages of tumor progression between the TME and CSC’s. This session aims to provide an insight into the role and importance of CSC’s in the context of the ME as well as examine the clinical implications of targeting these interactions.

Topics to be covered include:
• Current state of the art for modelling the TME interactions in the context of the CSC niche.
• The importance of CSC TME interactions alongside potential therapeutic targets for the development of more effective treatments against cancer
• The significance of stromal cells, immune cells, extracellular matrix, tumor stiffness, and hypoxia in regulation of CSC plasticity and therapeutic resistance

Time: 7:30 am - 5:00 pm